TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03171727
Drug: low molecular weight heparin
Normalized name: Low molecular weight heparin
Approvals — FDA: no, EMA: no, PMDA: no
Description: After TIPS procedure was performed, low molecular weight heparin was given for three days.
Study: NCT01854645
Drug: GP MDI
Normalized name: carbetapentane citrate / guaifenesin Oral Solution [Pulmari-GP]
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP MDI administered as two puffs BID
Study: NCT00947518
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cleansing the skin (except the face)with baby wipes containing normal saline
Study: NCT04130919
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablets administered orally once daily
Study: NCT00700284
Drug: placebo vaginal ring
Approvals — FDA: no, EMA: no, PMDA: no
Description: vaginal ring containing no TMC120 (dapivirine)
Study: NCT03826485
Drug: PRIC
Normalized name: APRICOT
DrugBank: Apricot (DB10502)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pranlukast hydrate 50mg
Study: NCT02118753
Drug: Eplerenone
Normalized name: Eplerenone
DrugBank: Eplerenone (DB00700)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: eplerenone administered ex vivo (to the organ bath in which human atrial tissue is exposed)
Study: NCT02647554
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo every 8 hours for 10 days
Study: NCT01427803
Drug: Naproxen Sodium ER (BAYH6689)
Normalized name: naproxen Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: BAYH6689; oral tablet used as needed upon incidence of pain
Study: NCT02777931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo capsules
Study: NCT01430104
Drug: Alfarol 1.0 µg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally throughout the study
Study: NCT03888716
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 and 100 mg placebo encapsulated tablets
Study: NCT00662714
Drug: short-acting Insulin (Actrapid)
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: initial dose: 3x 0.05E/kg/d, injected; 2 years
Study: NCT05288673
Drug: ALXN1210
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1210 was administered by IV infusion over 5 periods, 1 dose per period: Period 1, induction; Periods 2-5, maintenance. Participants received a total of 5 doses of 400 or 800 mg, each administered every 28 days.
Study: NCT05288673
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was administered by IV infusion over 5 periods, 1 dose per period. Participants received the same volume and infusion rate as specified for each ALXN1210 dose (400 or 800 mg).
Study: NCT00807625
Drug: Depo Provera
Approvals — FDA: no, EMA: no, PMDA: no
Description: Depo Provera administered by injection at randomization visit and the 12-week study visit.
Study: NCT04140903
Drug: Early transition to oral antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with an oral antibiotic regimen (e.g. amoxicillin + metronidazole) based upon pharmacokinetic and pharmacodynamic properties of the drugs, pathogen susceptibility, and any existing drug allergies or interactions
Study: NCT04140903
Drug: Standard treatment of intravenous antibiotics
Normalized name: combinations of different antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will continue standard intravenous antibiotic therapy for brain abscess (e.g. 3rd generation cephalosporin + metronidazole) according to international guidelines and pathogen susceptibility patterns.
Study: NCT04643470
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match zanubrutinib
Study: NCT01464983
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 500 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Acetylsalicylic acid, and 2 Placebo tablets of Ibuprofen
Study: NCT01464983
Drug: Acetylsalicylic acid (Aspirin, BAYE4465)
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid 2 x 500 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Ibuprofen
Study: NCT01464983
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 200 mg orally, single dose, 1 tablet; in addition, 1 Placebo tablet of Ibuprofen, and 2 Placebo tablets of Acetylsalicylic Acid
Study: NCT01464983
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 2 x 200 mg orally, single dose, 2 tablets; in addition, 2 Placebo tablets of Acetylsalicylic Acid
Study: NCT01464983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 Placebo tablets of Acetylsalicylic Acid, and 2 Placebo tablets of Ibuprofen, orally, single dose
Study: NCT00354900
Drug: Aprotinin
Normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03792984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO for 8 weeks.
Study: NCT01162395
Drug: AZD3514
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given AZD3514 orally as a single dose, and then multiple once daily dosing following a 5-9 day washout.
Study: NCT02003222
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT02003222
Drug: Leucovorin Calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV or PO
Study: NCT02003222
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given PO
Study: NCT02003222
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO, IT or IV
Study: NCT02122471
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02629809
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00124449
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution, intravenous injection, 0 mg, monthly, 169 days
Study: NCT01803477
Drug: once daily for two consecutive days (Picato)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03047954
Drug: Placebo - Cap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo capsule administered
Study: NCT04484922
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: continuous infusion of normal saline during the surgery
Study: NCT01871987
Drug: FK949E
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT02714634
Drug: Methotrexate + targeted therapy administration
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: * Methotrexate or leflunomide + adalimumab or~* Methotrexate or leflunomide + certolizumab or~* Methotrexate or leflunomide + etanercept or~* Methotrexate or leflunomide + golimumab or~* Methotrexate or leflunomide + infliximab or~* Methotrexate or leflunomide + abatacept or~* Methotrexate or leflunomide + rituximab or~* Methotrexate or leflunomide + tocilizumab or~* Methotrexate or leflunomide + sarilumab or~* Methotrexate or leflunomide + filgotinib or~* Methotrexate or leflunomide + upadacitinib or~* Methotrexate or leflunomide + Tofacitinib or~* Methotrexate or leflunomide + baricitinib
Study: NCT02714634
Drug: methotrexate or leflunomide + sulfasalazine + hydroxychloroquine administration
Normalized name: Leflunomide
DrugBank: Leflunomide (DB01097)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03111069
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dose Escalation: Heated Doxorubicin delivered by Hyperthermic Intraperitoneal Chemotherapy (HIPEC). After abdominal surgery two large bore catheters are placed in the peritoneal cavity through the incision. Starting dose of Doxorubicin is 15 mg/L of HIPEC perfusate.~Dose Expansion Starting Dose: MTD from Dose Escalation.
Study: NCT02836600
Drug: LY3039478
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered orally
Study: NCT04251585
Drug: Regular Novolin R
Normalized name: insulin, regular, human Injectable Solution [Novolin R]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal insulin
Study: NCT04251585
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intranasal placebo (0.9% saline)
Study: NCT04008355
Drug: Placebo oral solution
Normalized name: Placebo Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily intake in the morning
Study: NCT02122731
Drug: Amiloride
Normalized name: Amiloride
DrugBank: Amiloride (DB00594)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 mg(daily of amiloride was added to patients triple antihypertensive therapy and increased to 10 mg/daily if office blood pressure at 4 weeks was above 130/80 mmHg.
Study: NCT03958474
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants with a history of IV opioid use can opt to complete a session in which they receive remifentanil.
Study: NCT03975647
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given twice per day orally
Study: NCT02770261
Drug: Rosuvastatin 20mg
Normalized name: ROSUVASTATIN 20MG CAP,SPRINKLE
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study: NCT02770261
Drug: DP-R208 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg
Study: NCT02770261
Drug: Rosuvastatin 20mg Placebo
Normalized name: rosuvastatin 20 MG
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo
Study: NCT02359162
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 10 mg/m 2 /day 24 h continuous infusion on days 1-4
Study: NCT02359162
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: cyclophosphamide 750 mg/m2 /day over 15 min intravenously on day 5
Study: NCT03895359
Drug: Transarterial Chemoembolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transarterial chemoembolization is a standard treatment for patients with hepatocellular carcinoma (liver cancer). Chemotherapy is injected into the arteries of the liver and liver cancer.
Study: NCT02788474
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02236481
Drug: TNF alpha inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01115803
Drug: LY2584702
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplied as 25 milligrams (mg) and 100 mg capsules, administered orally for two 28-day cycles.
Study: NCT02815488
Drug: Placebo (Part 1 - SAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of placebo matching CHF6297 at each period (for up to 3 periods per subject)
Study: NCT02815488
Drug: Placebo (Part 2 - MAD)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses of placebo matching CHF6297 for 7 days
Study: NCT02815488
Drug: Placebo (Part 3)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses of placebo matching CHF6297 for 14 days
Study: NCT02815488
Drug: Placebo (Part 4)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily doses of placebo matching CHF6297 for 7 days
Study: NCT02000050
Drug: FOLFOX4
Approvals — FDA: no, EMA: no, PMDA: no
Description: FOLFOX4
Study: NCT02513563
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive AZD1775 225 mg twice daily, days 1 and 2 and once a day on day 3 (5 doses) during each 21 day cycle of treatment.
Study: NCT03292133
Drug: EGF816
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF816 is an inhibitor which target a specific mutation in cancer and may stop tumors growing and multiplying
Study: NCT02631356
Drug: Ringer's lactate solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02548468
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04304950
Drug: Morning Group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will take their IBD medication (either azathioprine or 6-mercaptopurine) between 6:00 am and 11:00 am.
Study: NCT04171388
Drug: Azithromycin 500 mg
Normalized name: azithromycin 500 MG
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Azithromycin 500mg (Kern Pharma): 2g (4 tablets) at 2 time points during pregnancy: enrollment (\<=24 weeks gestation), and follow-up ANC at least 4 weeks later
Study: NCT04171388
Drug: Placebo oral tablet 500 mg
Normalized name: placebo Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 500mg (Idifarma): 2g (4 tablets) at 2 time points during pregnancy; enrollment (\<24 weeks gestation), and follow up ANC at least 4 weeks later
Study: NCT02829983
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Use of 500mg of Clarithromycin twice a day for 3 days
Study: NCT02829983
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of placebo tablets twice a day for 3 days.
Study: NCT03178422
Drug: NicoDerm CQ Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nicotine Replacement Therapy
Study: NCT02874963
Drug: Non Surgical Periodontal Treatment includes post operative mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Previous to surgery procedures, in particular in the two groups with an adjunctive non surgical periodontal treatment such as full mouth tooth cleaning will be included mouth wash with Listerine® (ethanol 21.6%, methyl salicylate 0.06%, menthol 0.042%, thymol 0.064% and eucalyptol 0.092%) for the 3 weeks after tooth extraction and cleaning.
Study: NCT04136171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eplontersen-matching placebo by subcutaneous injection
Study: NCT03611686
Drug: Local chemotherapy
Normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local chemotherapy will be administrated according to local recommendation
Study: NCT03298672
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution for subcutaneous injection
Study: NCT04528628
Drug: SSRIs/SNRIs (Selective Serotonin Reuptake Inhibitors/ Serotonin and Norepinephrine Reuptake Inhibitors)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be treated with one kind of selective serotonin reuptake inhibitors/ serotonin and norepinephrine reuptake inhibitors. Dose is titrated to the minimum effective dose within 2 weeks. Benzodiazepines can be used for a short period lasting no more than 2 weeks.
Study: NCT04528628
Drug: Treatment as Usual
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: The research doctor discusses the treatment plan with the patient, and therapies and drugs are not limited.
Study: NCT03558997
Drug: Placebo matching SCIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching SCIT was prepared in the same formulation (SCIT diluent) without the addition of Timothy grass extract
Study: NCT02017171
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive oral tablets identical in appearance to allopurinol tablets.
Study: NCT03800290
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily ingestion of placebo capsules for a total period of 14 days with a wash-out period of 4 weeks.
Study: NCT00418665
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects in the control group will receive placebo via subcutaneous injection.
Study: NCT00345189
Drug: CNF2024
Approvals — FDA: no, EMA: no, PMDA: no
Description: CNF2024 capsules administered orally following 2 schedules:~* starting dose of 25 mg, twice a week for 3 weeks out of a 4-week course (Schedule 1) or~* starting dose of 600 mg twice a week for 4 weeks out of a 4-week course (without drug holidays; Schedule 2).~Treatment repeats every 28 days in the absence of disease progression or unacceptable toxicity. Dose escalation proceeds according to the predetermined scheme until the stopping dose is reached due to a dose limiting toxicity (DLT) occurring during the first 4-week course of treatment.
Study: NCT04485273
Drug: Local Anesthetic Solution and Dexmedetomedine
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg), in addition to dexmedetomedine (0.5 μg /kg)
Study: NCT04485273
Drug: Local Anesthetic Solution
Normalized name: Gelato Anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: The local anesthetic solution is injected with a dose of 0.5% bupivacaine (0.08 ml/kg).
Study: NCT00071266
Drug: Niacin Extended Release and Lovastatin Tablets
Normalized name: lovastatin / niacin Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00079014
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Given IV
Study: NCT03783702
Drug: Ibuprofen 600 Mg (milligram) Oral Tablet
Normalized name: ibuprofen 600 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients in the experimental group will receive ibuprofen 600mg as the second-line analgesic.
Study: NCT03783702
Drug: Acetaminophen 650 MG (milligram) Oral Tablet
Normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive acetaminophen as the first-line analgesic.
Study: NCT02198339
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02056405
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 pill of the same characteristics as Mosapride every 8 hs with 30 ml tap water. This will begin on postoperative day 1 until discharge from Hospital or unacceptable toxicity develops.
Study: NCT00931385
Drug: bi1744
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1744 low dose
Study: NCT00931385
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Respimat and Foradil Placebo
Study: NCT02778763
Drug: CBLB612
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 μg CBLB612 SQ
Study: NCT02778763
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02296125
Drug: AZD9291 80 mg/40 mg + placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The initial dose of AZD9291 80 mg once daily can be reduced to 40 mg once daily under specific circumstances. A cycle of treatment is defined as 21 days of once daily treatment.~Number of Cycles: as long as patients are continuing to show clinical benefit, as judged by the Investigator, and in the absence of discontinuation criteria.
Study: NCT00469261
Drug: Doxycycline
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycycline 100 mg bid for seven days after enrollment
Study: NCT00469261
Drug: Current medical therapy for AMI
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current medical therapy for AMI
Study: NCT01064245
Drug: high-dose methacholine challenge test
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulized liquid inhalation, 0.0625 - 256 mg/mL, doubling doses
Study: NCT02360657
Drug: JNJ-54861911, 10 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911, 10 mg (2\*5 mg tablet) orally once daily for 4 weeks.
Study: NCT02360657
Drug: JNJ-54861911, 50 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: JNJ-54861911, 50 mg (2\*25 mg tablet) orally once daily for 4 weeks.
Study: NCT02360657
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to JNJ-54861911 tablet orally once daily for 4 weeks.
Study: NCT02431481
Drug: LEE011
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg
Study: NCT00066807
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Planned duration of chemotherapy: 2 months if an anthracycline is included (e.g., 4 cycles of EC or AC) or 4 months if no anthracycline is given (e.g., 6 cycles of CMF) is recommended. Unless medically contraindicated, an anthracycline-containing regimen using epirubicin should be given.
Study: NCT02123628
Drug: duration of the antibiotic therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01418729
Drug: Pravastatin
Normalized name: Pravastatin
DrugBank: Pravastatin (DB00175)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment:~Patients will be randomized in two groups, A and B:~* Control Group (A ≡ 1): Patients will receive treatment with sorafenib 400 mg/12 h + placebo/24 h.~* Experimental Group (B ≡ 2): The treatment received will be sorafenib 400 mg/12 h + pravastatin 40 mg/24 h.
Study: NCT03457493
Drug: DPA-714-PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPA-714-PET/MRI
Study: NCT03457493
Drug: 5-year Follow-up DPA-714-PET/MRI
Approvals — FDA: no, EMA: no, PMDA: no
Description: PET/MRI scan with DPA-714
Study: NCT04640545
Drug: LBL-007
Approvals — FDA: no, EMA: no, PMDA: no
Description: LBL-007 will be administered intravenously every two weeks (Q2W) at doses of Dose A, Dose B, Dose C,Dose D .
Study: NCT00209651
Drug: Campto, Topotesin
Approvals — FDA: no, EMA: no, PMDA: no
Description: q00 mg/m2, IV (in the vein) on day 1,15 of each 28 day cycle.
Study: NCT01052467
Drug: Xamiol® Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once daily application for about 4 weeks
Study: NCT02686281
Drug: GMC-252-L-Lysine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02489903
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00005960
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00005960
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03455335
Drug: 20 million hMSCs
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03455335
Drug: 40 million hMSCs
Approvals — FDA: no, EMA: no, PMDA: no